A Phase 1/2 interventional study of TPX-0005 and Trametinib in KRAS Mutation-Related Tumors, Metastatic Solid Tumor and Advanced Solid Tumor, sponsored by Turning Point Therapeutics, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by Turning Point Therapeutics, Inc. (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.
Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 40th largest by enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 9 in phase 1/2, and was the 41st registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:
Turning Point Therapeutics, Inc. · Sites in United States, Australia, Canada and 8 more countries
Ages up to 25
By country, each count listing its studies:
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 23 · Phase 3 7
First in 2000; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 66 across the 44 interventional studies, 509 across the 5 observational. Of the 39 that completed or were terminated, 14 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Turning Point Therapeutics, Inc., one of the names counted as Bristol-Myers Squibb. Under that name alone:
Turning Point Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
1 of the studies in Neoplasm Metastasis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05165264Bristol-Myers SquibbA Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Phase 1 Dose Escalation: To evaluate tolerability of repotrectinib at increasing dose levels in combination with other anticancer therapies for the treatment of subjects with locally advanced or metastatic KRAS-mutant solid tumors
Phase 2 Efficacy Evaluation: Investigate the anti-tumor efficacy and safety of repotrectinib in combination with other anticancer therapies for the treatment of patients with locally advanced or metastatic KRAS-mutant solid tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TPX-0005 + Trametinib Dose Escalation and Dose Expansion Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC
Drug: TPX-0005 · Drug: Trametinib
Oral TPX-0005 capsules
Also known as: repotrectinib
Oral trametinib tablets
Also known as: Mekinist
Number of Participants With Dose Limiting Toxicities
Number of participants with first cycle DLTs to determine Mean Tolderable Dose (MTD) and/or RP2D. A DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications that meets the criteria defined in each subprotocol. The MTD is defined as the highest dose level of repotrectinib given in combination with other anticancer therapy observed to cause a DLT in fewer than 33% of the treated subjects in the first treatment cycle (i.e., Cycle 1).
Time frame: From initial dose to end of first cycle of treatment, approximately 28 days
Overall Response Rate (ORR) Assessed the Investigator Using RECIST v1.1.
The ORR will be defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR). A confirmed response is a response that persists on a repeat imaging performed at least 4 weeks after initial documentation of response. Participants with a confirmed objective response (CR or PR) will be referred to as responders. Radiographic confirmation of objective tumor response (CR or PR) or disease progression will be based on RECIST v1.1. The ORR will be reported as the percentage of responders by RECIST v1.1 along with the corresponding two-sided 95% Clopper-Pearson exact CI. Complete Response (CR) = Disappearance of all target lesions Partial Response (PR) = \>=30% decrease in the sum diameters of target lesions.
Time frame: From screening to end of treatment approximately 10 months
Cmax of Repotrectinib
Cmax is defined as maximum plasma concentration of the drug.
Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22
Tmax of Repotrecitinib
Tmax is defined is the time to maximum plasma concentration
Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22
AUC 0-24 of Repotrecitinib
Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.
Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22
Cmax of Trametinib
Cmax is defined as maximum plasma concentration of the drug.
Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22
Tmax of Trametinib
Tmax is defined is the time to maximum plasma concentration
Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22
AUC 0-24 of Trametinib
Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.
Time frame: At Cycle 1 Day 1 and Cycle 1 Day 22
| Milestone | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Started | 2 | 5 | 2 |
| Completed | 0 | 0 | 0 |
| Not completed | 2 | 5 | 2 |
| Withdrew: Death | 1 | 2 | 0 |
| Withdrew: Other reasons | 1 | 3 | 2 |
Number of participants with first cycle DLTs to determine Mean Tolderable Dose (MTD) and/or RP2D. A DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications that meets the criteria defined in each subprotocol. The MTD is defined as the highest dose level of repotrectinib given in combination with other anticancer therapy observed to cause a DLT in fewer than 33% of the treated subjects in the first treatment cycle (i.e., Cycle 1).
| Participants | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 2 | 0 | 2 |
The ORR will be defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR). A confirmed response is a response that persists on a repeat imaging performed at least 4 weeks after initial documentation of response. Participants with a confirmed objective response (CR or PR) will be referred to as responders. Radiographic confirmation of objective tumor response (CR or PR) or disease progression will be based on RECIST v1.1. The ORR will be reported as the percentage of responders by RECIST v1.1 along with the corresponding two-sided 95% Clopper-Pearson exact CI. Complete Response (CR) = Disappearance of all target lesions Partial Response (PR) = \>=30% decrease in the sum diameters of target lesions.
| Percentage of Participants | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Overall Response Rate (ORR) Assessed the Investigator Using RECIST v1.1. | — | 0 (0.0 to 60.2) | — |
Cmax is defined as maximum plasma concentration of the drug.
| ng/mL | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Cycle 1 Day 1 | 656.85 ± 37.88 | 570.86 ± 66.02 | 569.27 ± 20.26 |
| Cycle 1 Day 22 | — | 411.83 ± 49.37 | — |
Tmax is defined is the time to maximum plasma concentration
| hours (h) | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Cycle 1 Day 1 | 3.00 (2.00 to 4.00) | 2.00 (1.00 to 6.00) | 4.00 (4.00 to 4.00) |
| Cycle 1 Day 22 | — | 3.00 (2.00 to 4.00) | — |
Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.
| h*ng/mL | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Cycle 1 Day 1 | 6208.74 ± 82.59 | 6692.13 ± 57.48 | 8327.26 ± 25.27 |
| Cycle 1 Day 22 | — | 5223.89 ± 31.06 | — |
Cmax is defined as maximum plasma concentration of the drug.
| ng/mL | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Cycle 1 Day 1 | 15.24 ± 20.55 | 3.30 ± 69.58 | 2.60 ± 29.74 |
| Cycle 1 Day 22 | — | 10.55 ± 56.36 | — |
Tmax is defined is the time to maximum plasma concentration
| hours (h) | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Cycle 1 Day 1 | 1.50 (1.00 to 2.00) | 2.00 (1.00 to 2.00) | 2.00 (2.00 to 2.00) |
| Cycle 1 Day 22 | — | 2.50 (1.00 to 4.00) | — |
Area under the plasma concentration time-curve. AUC from time 0 to 24 hours after dose.
| h*ng/mL | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Cycle 1 Day 1 | 88.77 ± 6.48 | 20.58 ± 36.19 | 19.27 ± 13.47 |
| Cycle 1 Day 22 | — | 197.45 ± 45.52 | — |
Collected over From first dose to 28 days after last dose, approximately 9.5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1 | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Dose Level 2 | 2/5 (40%) | 1/5 (20%) | 5/5 (100%) |
| Dose Level -2a | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| Event | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/2 | 0/5 | 1/2 |
| AstheniaGeneral disorders | 0/2 | 0/5 | 1/2 |
| Atrial fibrillationCardiac disorders | 0/2 | 1/5 | 0/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/2 | 1/5 | 0/2 |
| Event | Dose Level 1 | Dose Level 2 | Dose Level -2a |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/2 | 2/5 | 1/2 |
| VomitingGastrointestinal disorders | 2/2 | 2/5 | 1/2 |
| AnaemiaBlood and lymphatic system disorders | 1/2 | 2/5 | 0/2 |
| VertigoEar and labyrinth disorders | 0/2 | 0/5 | 1/2 |
| ConstipationGastrointestinal disorders | 1/2 | 2/5 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 1/2 | 1/5 | 0/2 |
| Dry mouthGastrointestinal disorders | 1/2 | 0/5 | 0/2 |
| AstheniaGeneral disorders | 0/2 | 2/5 | 1/2 |
| Catheter site oedemaGeneral disorders | 0/2 | 0/5 | 1/2 |
| FatigueGeneral disorders | 1/2 | 2/5 | 1/2 |
| Age, Continuous(Years) | Dose Level 1 | Dose Level 2 | Dose Level -2a | Total |
|---|---|---|---|---|
| Mean | 59.5 ± 21.92 | 61.8 ± 12.74 | 60.5 ± 13.44 | 61.0 ± 12.84 |
| Sex: Female, Male(Participants) | Dose Level 1 | Dose Level 2 | Dose Level -2a | Total |
|---|---|---|---|---|
| Female | 2 | 4 | 1 | 7 |
| Male | 0 | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Dose Level -2a | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 3 | 2 | 7 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Dose Level 1 | Dose Level 2 | Dose Level -2a | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 0 | 5 | 1 | 6 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Mar 2023, 17 months.
Results were first posted in Apr 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Repotrectinib
Turning Point Therapeutics, Inc. →